LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

LLY

1,105.05

-0.35%↓

JNJ

207.73

+0.45%↑

ABBV

227.54

-1.85%↓

UNH

329.68

+1.07%↑

AZN

93.37

+0.12%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

26.77 1.36

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

25.89

Max

26.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
EPS	-1.01
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-3.2M -66M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+107.71% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	244M 1.7B
Vorige openingsprijs	25.41
Vorige sluitingsprijs	26.77

Nieuwssentiment

By Acuity

50%

163 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 nov 2025, 17:44 UTC

Winsten

Belangrijke Marktbewegers

Deere Warns of Tough Year Ahead as Earnings, Sales Fall -- Update

27 nov 2025, 00:00 UTC

Marktinformatie

Rio Tinto's Coming Investor Briefing Seen Focused on Costs, Lithium, Asset Sales -- Market Talk

26 nov 2025, 23:47 UTC

Marktinformatie

Nikkei May Rise as Fears About Potential AI Bubble Ease -- Market Talk

26 nov 2025, 23:28 UTC

Marktinformatie

Mortgage Refinancing in New Zealand Will Spur Recovery -- Market Talk

26 nov 2025, 23:21 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

26 nov 2025, 23:21 UTC

Marktinformatie

RBNZ Rate Cuts Finally Getting Traction With Consumers -- Market Talk

26 nov 2025, 23:02 UTC

Marktinformatie

Steelmaking Coal Price Signal Knocked by China Import Shift -- Market Talk

26 nov 2025, 21:38 UTC

Winsten

These Stocks Moved the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26 nov 2025, 21:25 UTC

Winsten

Li Auto Posts Surprise Loss, Stock Rises. What's Next for Its Diving EV Sales. -- Barrons.com

26 nov 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Commercial Metals Co Announces Closing of $2B Senior Notes Offering

26 nov 2025, 21:16 UTC

Winsten

Deere Beat Earnings Estimates. Why the Stock Is Falling. -- Barrons.com

26 nov 2025, 21:09 UTC

Winsten

Roblox Isn't Playing Games. Why the Stock Could -2-

26 nov 2025, 21:09 UTC

Winsten

Roblox Isn't Playing Games. Why the Stock Could Jump 50%. -- Barrons.com

26 nov 2025, 20:27 UTC

Acquisities, Fusies, Overnames

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26 nov 2025, 20:25 UTC

Acquisities, Fusies, Overnames

Charter Communications Stock Is a Disaster. The Answer Could Be a 10% Dividend. -- Barrons.com

26 nov 2025, 20:15 UTC

Winsten

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26 nov 2025, 20:08 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

26 nov 2025, 20:06 UTC

Marktinformatie

U.S. Natural Gas Settles Higher Ahead of Holiday -- Market Talk

26 nov 2025, 19:30 UTC

Winsten

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26 nov 2025, 19:21 UTC

Acquisities, Fusies, Overnames

Teck Resources: ISS and Glass Lewis Recommend Teck Hldrs Vote for Anglo American Deal

26 nov 2025, 18:43 UTC

Marktinformatie

U.S. Natural Gas Storage Down for Second Straight Week -- Market Talk

26 nov 2025, 18:41 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 12 to 407 -- Market Talk

26 nov 2025, 18:19 UTC

Winsten

Workday Beat Earnings Estimates. The Stock Is Down 10% Anyway. -- Barrons.com

26 nov 2025, 17:51 UTC

Winsten

Deere Forecasts Higher Tariff Costs, Less Profit in 2026 -- WSJ

26 nov 2025, 17:50 UTC

Winsten

These Stocks Are Moving the Most Today: Alphabet, Nvidia, AMD, Apple, Dell, Robinhood, Deere, HP Inc., Urban Outfitters, and More -- Barrons.com

26 nov 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

26 nov 2025, 17:20 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

26 nov 2025, 17:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

26 nov 2025, 17:16 UTC

Winsten

Acquisities, Fusies, Overnames

Blue Owl Is Having a Rough Year. Its Co-CEO Says -2-

26 nov 2025, 17:16 UTC

Winsten

Acquisities, Fusies, Overnames

Blue Owl Is Having a Rough Year. Its Co-CEO Says Investors' Fears Are 'Ungrounded.' -- Barrons.com

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

107.71% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 54.67 USD 107.71%

Hoogste 90 USD

Laagste 21 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

163 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.